Schurer, M., Patel, R., van Keep, M., et al. Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model. Frontiers in Medical Technology (2023). Available at: https://doi.org/10.3389/fmedt.2023.1010247
Dunlop, W., van Keep, M., Elroy, P. et al. Cost-Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective. PharmacoEconomics Open (2021). Available at: https://doi.org/10.1007/s41669-021-00301-7
Mehra, R., Yong, C., Seal, B., van Keep, M., Raad, A., and Zhang, Y. (2021). Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective, Journal of the National Comprehensive Cancer Network, 19(2), 153-162. Available at: https://jnccn.org/view/journals/jnccn/19/2/article-p153.xml
Seal B, Mooradian MJ, Van Keep M, Dunlop W, Brannman L and Yong C. Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US- An Update Based on 4-Year Survival Data. ISPOR 2021 Montreal, Canada. PCN44.
Mooradian MJ, Taylor S, Ramsden R, van Keep M, Dunlop W, Brannman L and Yong C. Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 5-Year Pacific Data. ISPOR 2021, Copenhagen, Denmark. POSC110.
Schurer M, Matthijsse SM, Vossen CY, van Keep M, Horscroft J, Chapman AM and Akehurst RL. Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands. Value in Health. 2021. Available at: https://doi.org/10.1016/j.jval.2021.08.003
Sun S, Wu Y, McDermott M and van Keep M. Cost-effectiveness model of recombinant FVIII versus emicizumab treatment of patients with severe hemophilia A without inhibitors. 61st American Society of Hematology Annual Meeting. Orlando, FL, USA. 7–10 December 2019. Poster 2102. Abstract available at: https://ashpublications.org/blood/article/134/Supplement_1/2102/428051/Cost-Effectiveness-Model-of-Recombinant-FVIII
Schurer M, Vossen CY, van Keep M, Horscroft J, Moorhouse JA, Chapman AM and Akehurst RL. Varying willingness-to-pay based on disease burden: Impact on health technology assessment outcomes of specialist drugs in the Netherlands. 19th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress Copenhagen, Denmark. 2–6 November 2019. PMU82. Available at: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3121/97941
Emery P, Van Keep M, Beard S, Graham C, Miles L, Jugl SM, Gunda P, Halliday A and Marzo-Ortega H. Cost-Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. Pharmacoeconomics. 2018; 36(8):1015-27. Available at: https://doi.org/10.1007/s40273-018-0675-9.
Emery P, van Keep M, Beard S, Graham C, Miles L, Jugl S, Gunda P, Halliday A and Marzo-Ortega H. Cost-effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK 20th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress Glasgow, Scotland. 4-8 November 2017. Poster PMS44. Available at: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/78476?pdfid=52019
van Keep M, Gairy K, Seshagiri D, Thilakarathne P and Lee D. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC Cancer. 2016; 16:598. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27488675.
van Keep M, Gairy K, Seshagiri D, Thilakarathne P and Lee D. Cost-effectiveness of bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) for the first-line treatment of mantle cell lymphoma not eligible for stem cell transplantation: A Scottish perspective. 18th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Milan, Italy. 7–11 November 2015. Poster PCN131.
Lee D, Nielsen SK, van Keep M, Andersson F and Greene D. Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer. J Urol. 2015; 193(3):839-46. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25264336
Henry TL, De Brouwer BF, Van Keep MM, Blankestijn PJ, Bots ML and Koffijberg H. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. J Med Econ. 2015; 18(1):76-87. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25367314.
Henry T, De Brouwer B, Van Keep M, Blankestijn P, Bots M and Koffijberg H. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. 17th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Amsterdam, The Netherlands. 8–12 November 2014. Poster PCV101.
Urbanus AT, van Keep M, Matser AA, Rozenbaum MH, Weegink CJ, van den Hoek A, Prins M and Postma MJ. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? PLoS One. 2013; 8(8):e70319. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23950920
van Keep MML, Huitema ADR, Schellens JHM and Beijnen JHE. New oncolytic agent for the treatment of metastatic breast cancer. Pharm Weekbl Sci. 2013; 7:60-4.